Featured Jobs
|
Relationship Manager for Defined Benefit/Cash Balance Plans Daybright Financial
|
|
MAP Retirement
|
|
BPAS
|
|
Retirement Plan Consultants
|
|
Managing Director - Operations, Benefits Daybright Financial
|
|
Southern Pension Services
|
|
Regional Vice President, Sales MAP Retirement USA LLC
|
|
Compass
|
|
Retirement Relationship Manager MAP Retirement
|
|
July Business Services
|
|
Mergers & Acquisition Specialist Compass
|
|
BPAS
|
|
Pentegra
|
|
ESOP Administration Consultant Blue Ridge Associates
|
|
BPAS
|
|
Retirement Plan Administration Consultant Blue Ridge Associates
|
|
Cash Balance/ Defined Benefit Plan Administrator Steidle Pension Solutions, LLC
|
|
Anchor 3(16) Fiduciary Solutions
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
Search the News Archive
|
3 Matching News Items |
| 1. |
Institute for Clinical and Economic Review [ICER]
Oct. 31, 2025
244 pages. "Despite these therapies being highly cost-effective, their potential budget impact is large.... [F]ewer than 1% of eligible patients could be treated at current and assumed net prices before crossing the ICER budget impact threshold of $880,000,000 annually. This raises serious concerns about affordability."
|
| 2. |
Faegre Drinker
June 9, 2021
"On May 12, 2021, the Institute for Clinical and Economic Review (ICER or the Institute) released plans to begin an annual examination into health insurance drug coverage policies to assess 'fair access' to prescription drugs.... The new project is notable because it marks a deepening of ICER's look at payer policies and how they impact beneficiary access to medications."
|
| 3. |
USA TODAY
May 27, 2016
"Insurance companies ... [have] cooked up a clever way to justify exclusions from formularies by founding and funding a group called the Institute for Clinical and Economic Review, or ICER.... ICER, which holds itself out as a kind of Consumer Reports for drugs, is basically an industry-backed comparative effectiveness calculator. That ICER is industry backed isn't the problem, it's that it uses comparative effectiveness to lend an air of legitimacy to the formulary shenanigans. Different people respond differently to medications. The blue pills don't always work the same as the red pills. Individuals, it turns out, are different."
|
|
Syntax Enhancements for Standard Searches
|